Search Results

By Syed Ali Abutalib, MD, and Shaji K. Kumar, MD  / September 25, 2020  / ASCO20 Virtual Scientific Program

Updates on BCMA-Directed CAR-Modified T-Cell Gene Therapies

Outcomes in patients with triple-class–failure relapsed and refractory multiple myeloma who experience disease progression on immunomodulatory agents, proteasome inhibitors, and CD38 antibodies are dismal. Most recently, early results of three anti-B-cell maturation antigen (BCMA) chimeric antigen...